A COST MINIMIZATION ANALYSIS OF AZELASTINE/FLUTICASONE COMBINATION NASAL SPRAY VERSUS AZELASTINE AND FLUTICASONE NASAL SPRAYS MONOTHERAPY IN MODERATE TO SEVERE ALLERGIC RHINITIS- AN EXPERIENCE FROM ISLAMIC REPUBLIC OF IRAN
Author(s)
Zaboli P1, Nikfar S1, Ayati N1, Rohani E2, Toroski M1, Babaie D3
1Tehran University of Medical Sciences, Faculty of Pharmacy, Tehran, Iran (Islamic Republic of), 2Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), 3Shahid Beheshti University of Medical Sciences, Tehran, Iran (Islamic Republic of)
OBJECTIVES: Allergic Rhinitis (AR) is a symptomatic disorder which is due to allergen exposure and IgE inflammatory pathway activation in respiratory tract. AR is categorized upon symptoms` type aand duration and its impact on patients` health related quality of life into mild and moderate to severe METHODS: A systematic review (SR) was performed to find relevent randomized clinical trials of Fluticasone/Azelastine (50μg/125μg), Fluticasone (50μg) and Azelastine (125μg) nasal sprays which evaluate their clinical effectivenesses. According to performed SR results, clinical effectiveness of two arms of study were approximately equal. Hence, a cost minimization analysis was done. As micro costing, direct medical costs (drugs` costs, GP office visits` costs, specialists` office visits` costs and allergy-related tests` costs), from official health tariffs book in I.R.I. were calculated from a payer perspective. Dollar currency rate was considered 32447.29 IRR/1$. Model time horizon was 14 day. Because of this short time horizon, discount rate was not applied. At last, a budget impact analysis was done according to AR incidence rate in I.R.I. RESULTS: Azelastine/Fluticasone combination nasal spray can save 2.05$ per patient for each course of treatment in AR patients in I.R.I. In addition, budget analysis results showed that it can minimize overall cost around 63755.5$ at the end of fifth year in AR patients I.R.I. CONCLUSIONS: This study showed that Azelastine/Fluticasone combination nasal spray is a cost saving alternative in I.R.I. health care system.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PRS43
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Respiratory-Related Disorders